Reference : Treatment of experimental asthma by decoy-mediated local inhibition of activator protein-1
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
Life sciences : Veterinary medicine & animal health
Treatment of experimental asthma by decoy-mediated local inhibition of activator protein-1
Desmet, Christophe mailto [Université de Liège - ULg > Département de sciences fonctionnelles > GIGA-R : Biochimie et biologie moléculaire >]
Gosset, P. [> > > >]
Henry, E. [> > > >]
Garze, V. [> > > >]
Faisca, P. [> > > >]
Vos, N. [> > > >]
Jaspar, Fabrice [Université de Liège - ULg > > Clinique des grands animaux >]
Burin Kefer, D. [ > > ]
Lambrecht, B. [> > > >]
Desmecht, Daniel mailto [Université de Liège - ULg > Département de morphologie et pathologie > Pathologie spéciale et autopsies >]
Pajak, B. [> > > >]
Moser, M. [> > > >]
Lekeux, Pierre mailto [Université de Liège - ULg > Département de sciences fonctionnelles > Physiologie >]
Bureau, Fabrice mailto [Université de Liège - ULg > Département de sciences fonctionnelles > Biochimie et biologie moléculaire >]
American Journal of Respiratory & Critical Care Medicine
Amer Thoracic Soc
Yes (verified by ORBi)
New York
[en] allergy ; eosinophils ; gene therapy ; lung ; transcription factors
[en] Rationale: Asthma is associated with increased expression of a typical array of genes involved in immune and inflammatory responses, including those encoding the prototypic Th2 cytokines interleukin (IL) 4, IL-5, and IL-13. Most of these genes contain binding sites for activator protein-1 (AP-1) within their promoter and are therefore believed to depend on AP-1 for their expression, suggesting that this transcription factor could be of particular importance in asthma pathophysiology. Objective: To clarify the role of AP-1 in the effector phase of pulmonary allergy. Methods: Ovalbumin (OVA)-sensitized mice were intratracheally given decoy oligodeoxyribonucleotides (ODNs) specifically directed to AP-1 or scrambled control ODNs before challenge with aerosolized OVA. Twenty-four hours after the last OVA challenge, airway hyperresponsiveness was measured and allergic airway inflammation was evaluated quantitatively. AP-1 decoys were localized using flow cytometry and immunohistochemistry. AP-1 activity in the lung was assessed using electrophoretic mobility shift assay. Measurements and Main Results: Intratracheally delivered AP-1 decoys efficiently targeted airway immune cells, thus precluding AP-1 activation on OVA challenge. Decoy-mediated local inhibition of AP-1 resulted in significant attenuation of all the pathophysiologic features of experimental asthma-namely, eosinophilic airway inflammation, airway hyperresponsiveness, mucous cell hyperplasia, production of allergen-specific immunoglobulins, and synthesis of IL-4, IL-5, and IL-13. Scrambled control ODNs had no detectable effects. Conclusions: Our results reveal a key role for AP-1 in the effector phase of pulmonary allergy and indicate that specific AP-1 inhibition in the airways may have therapeutic value in the control of established asthma.
Researchers ; Professionals

File(s) associated to this reference

Fulltext file(s):

Restricted access
DesmetCh_AmJRespCriticCareMed_2005.pdfPublisher postprint1.01 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.